Syngene International
Bengaluru, India
1 partnership announcement in press monitoring
· Last scored 2026-09-07
78.5
Signal Score
✓ FDA Inspections (1)
○ Clinical Trials
○ SEC Filings
✓ Press (9)
○ EMA GMP
○ MHRA GMP
Quick Facts: Syngene International
- Signal Score
- 78.5/100 (as of 2026-09-07)
- Quality Compliance
- 96.3/100
- Headquarters
- Bengaluru, India
- Modalities
- Biologics, Cell Therapy
- Active Programs
- Data pending
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Syngene International
Pure-play CDMO.
Signal Score & Pillar Breakdown
Scores are being republished.
Scores are being republished under methodology v3.3. The score shown is the last complete v3.2 result, which is also what directory listings and search results show. A pillar breakdown is not shown because the current one is computed under v3.3 and would not explain a v3.2 score. Regulatory evidence below is current.
Quality Compliance
96.3
FDA Inspections1 on record
Warning Letters0
Last InspectionNo Action Indicated (NAI) (2025-02-20)
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer. 1 partnership announcement found in press monitoring.
Programs
— no verified data
Sponsors— no verified data
ModalitiesBiologics, Cell Therapy
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Partnership Announcements (from press monitoring)
Financial Stability
68.0
Profile-based financial assessment
SEC FilingsPrivate company
Capacity
58.0
Profile-based capacity assessment
Recent Press9 articles
Syngene International FDA Inspection History
2025-02
NAI
VAI
OAI
| Date | Site | Type | Observations | Classification |
|---|---|---|---|---|
| 2025-02-20 |
Syngene International Ltd.
Bengaluru
Facility-linked
|
Drug Quality Assurance | No | No Action Indicated (NAI) |
Source: FDA Data Dashboard · Retrieved Oct 06, 2026
Attribution not established
(1)
These records are excluded from this company’s established evidence
because their attribution is unresolved. This describes an evidence-linking
limitation, not an assessment of the underlying regulatory findings.
| Source | Establishment named by the regulator | Location | Identifier |
|---|---|---|---|
| FDA inspection | LNK International, Inc. | Hauppauge, New York | FDA/FEI=2432212 |
Source records retained verbatim · attribution not established
Recent News 9 articles
Syngene International Reports Modest 3% FY26 Revenue Growth Amid Biologics Headwinds - IndiaMedToday
Syngene International Reports Modest 3% FY26 Revenue Growth Amid Biologics Headwinds IndiaMedToday
Syngene International Q4 net down 19 pc at Rs 147.9 cr - Devdiscourse
Syngene International Q4 net down 19 pc at Rs 147.9 cr Devdiscourse
Syngene International stock (INE398A01010): Is its CRO model strong enough to unlock new upside for - AD HOC NEWS
Syngene International stock (INE398A01010): Is its CRO model strong enough to unlock new upside for AD HOC NEWS
Syngene International stock (INE398A01010): Is its CRO model strong enough to unlock new upside for - AD HOC NEWS
Syngene International stock (INE398A01010): Is its CRO model strong enough to unlock new upside for AD HOC NEWS
Syngene International stock (INE398A01010): Is its CRO model strong enough to unlock new upside for - AD HOC NEWS
Syngene International stock (INE398A01010): Is its CRO model strong enough to unlock new upside for AD HOC NEWS
Syngene International stock faces headwinds amid contract research slowdown in Q3 FY26 - AD HOC NEWS
Syngene International stock faces headwinds amid contract research slowdown in Q3 FY26 AD HOC NEWS
Syngene International stock faces headwinds amid contract research slowdown in Q3 FY26 - AD HOC NEWS
Syngene International stock faces headwinds amid contract research slowdown in Q3 FY26 AD HOC NEWS
Syngene International Stock (ISIN: INE398A01010) Faces Pressure Amid Biopharma Contract Slowdown - ad-hoc-news.de
Syngene International Stock (ISIN: INE398A01010) Faces Pressure Amid Biopharma Contract Slowdown AD HOC NEWS
VivaMed BioPharma Partners With Syngene International to Advance AI-Derived Repurposed Therapeutic Programs Through Global Validation Infrastructure - BioSpace
VivaMed BioPharma Partners With Syngene International to Advance AI-Derived Repurposed Therapeutic Programs Through Global Validation Infrastructure BioSpace
Frequently Asked Questions About Syngene International
How many FDA inspections does Syngene International have on record?
CDMO Signal tracks 1 FDA inspection for Syngene International, sourced from the FDA inspection database. See the full inspection history above.
Has Syngene International received an FDA warning letter?
CDMO Signal has no FDA warning letters on record for Syngene International.
What is Syngene International's CDMO Signal Score?
Syngene International has a Signal Score of 78/100, based on quality, operations, financial stability, and capacity data.
Evaluating Syngene International for a manufacturing program?
Use the free AI matchmaker to compare Syngene International against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Merck KGaA / MilliporeSigma (CDMO)
Darmstadt, DE · St. Louis, MO
Signal Score: 81.8
mRNA, Biologics, Cell Therapy
Eurofins CDMO
Planegg, DE · San Diego, CA
Signal Score: 81.6
Biologics, Cell Therapy
Singota Solutions
Bloomington, IN
Signal Score: 59.0
Cell Therapy, Biologics
Biocon Biologics
Bengaluru, India
Signal Score: 77.6
Cell Therapy
Aurigene Pharmaceutical Services
Hyderabad, India
Signal Score: 63.0
Oligonucleotide, Biologics